ଟେପୋଟିନିବ
Clinical data | |
---|---|
Trade names | Tepmetko |
Synonyms | EMD-1214063 |
AHFS/Drugs.com | monograph |
data | |
Pregnancy category | |
Routes of administration | By mouth |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C29H28N6O2 |
Molar mass | ୪୯୨.୫୮ g·mol−1 |
3D model (JSmol) | |
| |
|
ଟେପୋଟିନିବ, ବେପାର ନାମ ଟେପମେଟକୋ, ବିକ୍ରି ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅଣ-ଛୋଟ ଜୀବକୋଷ ଫୁସଫୁସ କର୍କଟ (NSCLC) ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।[୪] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ମେଟାଷ୍ଟାଟିକ୍ ରୋଗରେ ବ୍ୟବହୃତ ହୁଏ ଯେଉଁଥିରେ ମେସେନକାଇମାଲ-ଏପିଥେଲିଆଲ ଟ୍ରାଞ୍ଜିସନ ଏକସନ (ଏମଇଟି/ MET) ସ୍କିପିଙ୍ଗ୍ ଥାଏ ।[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।[୪]
ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଫୁଲା, ଥକାପଣ, ଅଇ, ତରଳ ଝାଡ଼ା, ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା, କମ୍ ରକ୍ତ ସୋଡିୟମ୍ ଏବଂ ଅଣନିଶ୍ୱାସ ହୋଇପାରେ ।[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମୋନାଇଟିସ୍ ଏବଂ ଯକୃତ ସମସ୍ୟା ହୋଇପାରେ ।[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।[୪] ଏହା ଏକ କାଇନେଜ ଇନହିବିଟର ଯାହା ଏମଇଟିକୁ ଅବରୋଧ କରେ । [୪] [୭]
୨୦୨୦ରେ ଜାପାନରେ, ୨୦୨୧ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଓ ୨୦୨୨ରେ ୟୁରୋପରେ ଟେପୋଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।[୪][୮][୯] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୨ ମସିହାରେ ଏହାର ଏକ ମାସର ଖର୍ଚ୍ଚ ପ୍ରାୟ ୭୨୦୦ ପାଉଣ୍ଡ ଥିଲା । ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ୨୨୮୦୦ ଡଲାର ଅଟେ।[୧୦]
ଆଧାର
[ସମ୍ପାଦନା]- ↑ ୧.୦ ୧.୧ "Tepmetko APMDS". Therapeutic Goods Administration (TGA). 27 January 2022. Retrieved 5 February 2022.
{{cite web}}
: CS1 maint: url-status (link) - ↑ "Summary Basis of Decision (SBD) for Tepmetko". Health Canada. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
- ↑ "Tepmetko EPAR". European Medicines Agency (EMA). 14 December 2021. Archived from the original on 5 May 2022. Retrieved 5 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ ୪.୦ ୪.୧ ୪.୨ ୪.୩ ୪.୪ ୪.୫ ୪.୬ ୪.୭ ୪.୮ "Tepmetko- tepotinib hydrochloride tablet". DailyMed. Archived from the original on 27 November 2021. Retrieved 13 February 2021.
- ↑ "FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer". Food and Drug Administration. 3 February 2021. Archived from the original on 3 February 2021. Retrieved 3 February 2021. This article incorporates text from this source, which is in the public domain.
- ↑ "FDA Approves Tepmetko as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations". EMD Serono (Press release). 3 February 2021. Archived from the original on 4 February 2021. Retrieved 3 February 2021.
- ↑ "Tepmetko". EMA. Archived from the original on 5 May 2022. Retrieved 31 October 2022.
- ↑ "Tepmetko (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations" (Press release). Merck KGaA. 25 March 2020. Retrieved 3 February 2021.
- ↑ "Tepotinib". SPS - Specialist Pharmacy Service. 17 September 2019. Archived from the original on 21 January 2022. Retrieved 31 October 2022.
- ↑ "Tepmetko". Archived from the original on 31 October 2022. Retrieved 31 October 2022.